Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
Agile Therapeutics, Inc. (AGRX) will report its fourth quarter and full year 2023 financial results on March 28, 2024. A live conference call and webcast will follow to discuss the financial results and provide a business update.
03/21/2024 - 06:35 AM
Live Conference Call and Webcast at 8:30 a.m. ET
PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Thursday, March 28, 2024. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a business update.
Event Agile Therapeutics Fourth Quarter & Full Year 2023 Financial Results Conference Call Date Thursday, March 28, 2024 Time 8:30 a.m. ET / 5:30 a.m. PT
A live webcast of the conference call may be accessed via the Investor Relations portion of the Agile Therapeutics website at https://ir.agiletherapeutics.com/events-and-presentations . To participate in the live conference call via telephone, please register here . Upon registering, a dial-in number and unique PIN will be provided to join the conference call.
About Agile Therapeutics, Inc. Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla® , (levonorgestrel and ethinyl estradiol) transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion® , which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com . The Company may occasionally disseminate material, nonpublic information on the Company’s website and LinkedIn account.
Contact: Matt Riley
Head of Investor Relations & Corporate Communications
mriley@agiletherapeutics.com
When will Agile Therapeutics (AGRX) report its fourth quarter and full year 2023 financial results?
Agile Therapeutics (AGRX) will report its fourth quarter and full year 2023 financial results on Thursday, March 28, 2024.
What time will the live conference call and webcast to discuss Agile Therapeutics' (AGRX) financial results be held?
The live conference call and webcast to discuss Agile Therapeutics' (AGRX) financial results will be held at 8:30 a.m. ET on Thursday, March 28, 2024.
How can I access the live webcast of Agile Therapeutics' (AGRX) conference call?
The live webcast of Agile Therapeutics' (AGRX) conference call can be accessed via the Investor Relations portion of the Agile Therapeutics website at https://ir.agiletherapeutics.com/events-and-presentations.
How can I participate in the live conference call via telephone to discuss Agile Therapeutics' (AGRX) financial results?
To participate in the live conference call via telephone to discuss Agile Therapeutics' (AGRX) financial results, please register at the provided link. Upon registering, a dial-in number and unique PIN will be provided to join the conference call.
AGRX Rankings
N/A Ranked by Stock Gains
AGRX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Princeton
About AGRX
agile therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. our lead product candidate, twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as ag200-15, is a once-weekly prescription contraceptive patch that recently completed phase 3 trials. twirla is based on our proprietary transdermal patch technology, called skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. for more information, please visit the company website at www.agiletherapeutics.com. connect with us on twitter at @agilether.